A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing
Launched by MOLNLYCKE HEALTH CARE AB · Nov 1, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the healing process of chronic venous leg ulcers, which are wounds that don’t heal properly and often leak fluid. The researchers want to see how well a special type of foam dressing without borders helps these wounds heal over time. Participants in the study will need to wear this dressing for up to six weeks or until their wound is healed, with the dressing being changed every week.
To join the trial, participants need to be adults aged 18 or older who have been diagnosed with a chronic venous leg ulcer that has a moderate to large amount of fluid and falls within a specific size range. It's important that their blood flow to the legs is adequate and that they are willing to follow additional treatment guidelines, like wearing compression bandages. Those with infected wounds, certain types of wounds, or allergies to the dressing materials cannot participate. Throughout the trial, participants will have regular check-ups to monitor their wound's progress, and they can expect support from the healthcare team during the process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed consent to participate (including consent for digital imaging)
- • Adult aged ≥18 years
- • Diagnosed with a chronic, exuding VLU
- • Exudate amount moderate to large
- • Wound size from 3 cm2 to 30 cm2, as determined by the clinician
- • ABPI (within 3 months) \> 0.7. If ABPI \> 1.4, then big toe pressure \> 60 mmHg is required or an alternative measurement verifying normal distal arterial flow
- • Willing to be compliant with compression therapy
- Exclusion Criteria:
- • Infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment
- • Circumferential wound
- • Known allergy/hypersensitivity to the materials of the dressing
- • Use of wound fillers
About Molnlycke Health Care Ab
Mölnlycke Health Care AB is a global medical solutions company specializing in the development and manufacturing of innovative wound care and surgical products. With a strong commitment to enhancing patient outcomes, Mölnlycke combines extensive clinical expertise with advanced technology to deliver high-quality medical devices and solutions. The company operates with a focus on sustainability and collaboration with healthcare professionals, ensuring that their products meet the evolving needs of patients and healthcare systems worldwide. Through rigorous clinical trials and research, Mölnlycke continues to advance the field of healthcare, aiming to improve healing processes and promote patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Pittsburgh, Pennsylvania, United States
San Francisco, California, United States
Patients applied
Trial Officials
Hadar Lev-Tov, MD, MAS
Principal Investigator
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials